You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The approach uses miniaturized sample prep and isobaric tagging and can identify up to 2,300 proteins in single cells and analyze around 100 cells per day.
New instrumentation, reagents, and methods, as well as increasing interest in small and single-cell samples, could prove a boon for the technology.
The method combines stable isotope dimethyl labeling with DiLeu isobaric tagging and allows multiplexing of up to 24 samples in a single mass spec experiment.
The multiplexed proteomic approach could offer better sensitivity and accuracy than existing methods while working with a wider range of instrumentation.
The approach uses isobaric tagging to quantify proteins in single cells, and is one of the first to bring mass spec analysis to the single-cell level.
The company plans to use the money to speed its transition to a contract research business model, and to support its TMT reagents business.
The company hopes that looking at multiple species of the phosphorylated tau protein could allow for earlier and more accurate diagnosis of the disease.
The company, which has struggled to turn its broad proteomics expertise into steady profits, plans to focus more tightly on its pharma services business.
The firm is placing about 13.9 million new shares of its stock at 18 pence per share.
The UK-based proteomics and lipidomics firm will offer solutions to help healthcare professionals utilizing protein expression data in patient care.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.